1
|
Mueller C, Jonnalagadda S, Torres KA, Blackmer A, Cetnarowski W, Chen Y, Citty SW, Dye E, Hubbard VS, Kumbhat S, Ottery F, Russell ME, Sacks GS, Turner J. Importance of public-private partnerships for nutrition support research: An ASPEN Position Paper. JPEN J Parenter Enteral Nutr 2021; 45:1619-1626. [PMID: 34669195 DOI: 10.1002/jpen.2239] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Parenteral and enteral nutrition support are key components of care for various medical and physiological conditions in infants, children, and adults. Nutrition support practices have advanced over time, driven by the goals of safe and sufficient delivery of needed nutrients and improved patient outcomes. These advances have been, and continue to be, dependent on research and development studies. Such studies address aspects of enteral and parenteral nutrition support: formulations, delivery devices, health outcomes, cost-effectiveness, and related metabolism. The studies are supported by public funding from the government and by private funding from foundations and from the nutrition support industry. To build public trust in nutrition support research findings, it is important to underscore ethical research conduct and reporting of results for all studies, including those with industry sponsors. In 2019, American Society for Parenteral and Enteral Nutrition's (ASPEN's) Board of Directors established a task force to ensure integrity in nutrition support research that is done as collaborative partnerships between the public (government and individuals) and private groups (foundations, academia, and industry). In this ASPEN Position Paper, the Task Force presents principles of ethical research to guide administrators, researchers, and funders. The Task Force identifies ways to curtail bias and to minimize actual or perceived conflict of interests, as related to funding sources and research conduct. Notably, this paper includes a Position Statement to describe the Task Force's guidance on Public-Private Partnerships for research and funding. This paper has been approved by the ASPEN Board of Directors.
Collapse
Affiliation(s)
- Charles Mueller
- Department of Nutrition, Food Studies and Public Health, New York University, New York, New York, USA
| | | | | | - Allison Blackmer
- American Society for Parenteral and Enteral Nutrition (ASPEN), Silver Spring, MD
| | | | - Yimin Chen
- Margaret Ritchie School of Family and Consumer Sciences, University of Idaho College of Agricultural and Life Sciences, Moscow, Idaho, USA
| | | | | | | | - Seema Kumbhat
- Medical Affairs, Fresenius Kabi USA, LLC, Lake Zurich, Illinois, USA
| | - Faith Ottery
- Ottery & Associates, LLC, Deerfield, Illinois, USA
| | | | - Gordon S Sacks
- Medical Affairs, Fresenius Kabi USA, LLC, Lake Zurich, Illinois, USA
| | - Justine Turner
- Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
2
|
Rogers CA, Ahearn JD, Bartlett MG. Data Integrity in the Pharmaceutical Industry: Analysis of Inspections and Warning Letters Issued by the Bioresearch Monitoring Program Between Fiscal Years 2007-2018. Ther Innov Regul Sci 2020; 54:1123-1133. [PMID: 32096103 DOI: 10.1007/s43441-020-00129-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 02/09/2020] [Indexed: 10/24/2022]
Abstract
BACKGROUND Warning Letters issued by the Food and Drug Administration's Bioresearch Monitoring (BIMO) Program provide insight into data integrity issues and other research misconduct in the premarket side of the pharmaceutical industry. The objectives of this study were to understand the common compliance issues for clinical investigators, institutional review boards, sponsors of clinical studies, good laboratory practice laboratories, and bioequivalence studies and to see how compliance has changed over time. METHODS Warning letters and closeout letters issued by the BIMO program between US fiscal years 2007-2018 were analyzed by categorizing regulatory violations into violation themes. Inspections during the same time period were analyzed based on the assigned inspection classification. RESULTS A combined total of 300 warning letters were analyzed as a part of this study. The most common violations found in all warning letter categories included failing to follow and maintain procedures and poor documentation practices. Inspection results show that overall the percentage of Official Action Indicated results has decreased over time, while the percentage of No Action Indicated results has increased. CONCLUSION Although the number of warning letters has decreased over the past decade and inspection results have been improving, there are still significant data integrity and other regulatory compliance issues found in the premarket side of the pharmaceutical industry. It is unclear if the reduction of warning letters is due to improved compliance in the industry or other factors unrelated to compliance.
Collapse
Affiliation(s)
- Clinton A Rogers
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, 250 West Green Street, Athens, GA, 30602, USA
| | - Jennifer D Ahearn
- Pharmaceutical and Medical Devices, Engineering Systems, Inc, Norcross, GA, USA
| | - Michael G Bartlett
- Department of Pharmaceutical and Biomedical Sciences, University of Georgia, 250 West Green Street, Athens, GA, 30602, USA.
| |
Collapse
|
3
|
Yazici Y. Metaanalyses, Network Metaanalyses, and Systematic Reviews: The Perpetual Motion Machine All Over Again. J Rheumatol Suppl 2020; 47:1-3. [PMID: 31894089 DOI: 10.3899/jrheum.190900] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Yusuf Yazici
- New York University, School of Medicine, New York, New York, USA.
| |
Collapse
|
4
|
Garmendia CA, Nassar Gorra L, Rodriguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials. JAMA Intern Med 2019; 179:582-584. [PMID: 30830216 PMCID: PMC6450302 DOI: 10.1001/jamainternmed.2018.7661] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
This study evaluates the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses.
Collapse
Affiliation(s)
- Craig A Garmendia
- Office of Bioresearch Monitoring Operations, Office of Regulatory Affairs, US Food and Drug Administration, Miami, Florida
| | - Liliana Nassar Gorra
- Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami
| | - Ana Lucia Rodriguez
- Department of Psychology, School of Integrated Science and Humanity, Florida International University, Miami
| | - Mary Jo Trepka
- Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami
| | - Emir Veledar
- Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, Miami
| | - Purnima Madhivanan
- Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami
| |
Collapse
|